Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia | Morningstar

[GlobeNewswire](/news/globe-newswire) Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia - The first-in-human Phase 1 clinical study will evaluate the safety, to
Read more...